Status:
COMPLETED
Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The purpose of this study in patients with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the long-term efficacy and safety of subcutaneously...
Detailed Description
Coronary artery disease (CAD) is the leading cause of death in industrialized countries. Current revascularization therapies are PCI or surgical revascularization. However, inherent to them are proced...
Eligibility Criteria
Inclusion
- Age \> 18 years old
- 1- to 3-vessel coronary artery disease (CAD)
- Stable angina pectoris
- At least 1 stenotic lesion suitable for PCI
- No Q-wave myocardial infarction in the area undergoing CFI measurement
- Written informed consent to participate in the study
Exclusion
- Acute myocardial infarction
- Unstable CAD
- CAD treated best by CABG
- Patients with overt neoplastic disease
- Patients with diabetic retinopathy
- Liver or kidney disease
- Pre-menopausal women
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00886509
Start Date
March 1 2009
End Date
February 1 2015
Last Update
December 16 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Berne
Bern, Canton of Bern, Switzerland, 3010
2
University Hospital Berne
Bern, Switzerland, 3010